ANACETRAPIB - Watsons Health


Anacetrapib is a CETP inhibitor being developed to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease.

Anacetrapib reduces the transfer of cholesteryl ester from HDL to LDL and/or VLDL thereby, producing an increase in serum HDL-cholesterol levels and a decrease in serum LDL-cholesterol levels.

The large morbidity and mortality trial with anacetrapib, known as REVEAL and run by researchers at the University of Oxford, is currently ongoing, and full results are expected in 2017.

There is not enough information about the side effects of this drug. However, since it contains inactive ingredients, allergic reaction may be triggered.


The use of this drug has not approved yet due to insufficient data. There is an on-going research about this drug.



Research is still on-going there is no full result about it yet.

Data hasn’t proved yet that increasing HDL (or too much intake of this drug) is bad for someone’s health. Research about this is still on going.

Related Articles

DTP-HIB Vaccine

DTP-HIB vaccine is a combined vaccine of adsorbed diphtheria, tetanus toxoid and acellular pertussis and of Haemophilus influenzae type b conjugate vaccines. It is a [...]


Tenecteplase is a tissue-type plasminogen activator (tPA), a biosynthetic form of human enzyme that is a fibrin-specific thrombolytic agent, converting plasminogen to [...]


Selexipag is a selective non-prostanoid agonist of prostacyclin (IP) receptor, that stimulates the release of prostacyclin, which is responsible to induce [...]